NFKB1 and lymphoma: Accumulating evidence shows that the noncanonical NF-κB pathway is activated in the tumor cells of several human cancers, including B- and T-cell leukemia/lymphoma, mammary carcinoma, and prostate cancer [12], [17], [19], [20], [43], [53], [54].